The US Food and Drug Administration recently approved a new weight-loss pill named Foundayo, made by Eli Lilly. This daily pill joins the ranks of other GLP-1 medications, like Ozempic and Wegovy, which help manage weight by mimicking a hormone that regulates blood sugar and promotes a feeling of fullness.
Foundayo is noteworthy because it’s the second GLP-1 pill available, following Wegovy’s pill form approved last December. Unlike Wegovy’s prescription to take the pill on an empty stomach, Foundayo can be taken at any time, making it more convenient for users.
Demand for injectable GLP-1 medications has driven many pharmaceutical companies to create oral versions. Since injections may feel daunting for some, especially those who view them as a sign of a more severe condition, pills offer a more approachable option. Ken Custer, Eli Lilly’s EVP, noted that for many, starting with a pill can simplify their weight management journey.
In clinical trials, users of Foundayo lost an average of 27 pounds over 18 months, a significant contrast to just 2 pounds lost by those on a placebo. This development is promising, especially as weight management becomes more critical in the fight against obesity, which affects over 40% of American adults, according to the CDC.
As Foundayo becomes available through channels like LillyDirect and retail pharmacies, experts anxiously await its impact on patient choices. Research is ongoing about the active ingredient, orforglipron, which is also being explored for conditions like type 2 diabetes and obstructive sleep apnea.
The FDA expedited the approval process for Foundayo, completing it in just 50 days, a part of a program aimed at addressing urgent health priorities. This rapid approval reflects the growing emphasis on making effective treatments available quickly.
With the increasing popularity and availability of weight-loss medications, keeping informed about the options could empower patients on their health journeys.
Source link
medicine,pharmaceutical industry,science,glp-1
